Tumor-targeting prodrug-activating bacteria for cancer therapy

Cancer Gene Therapy

Volumn 15, Issue 6, 2008, Pages 393-401

  Cheng, C M ^a   Lu, Y L ^b   Chuang, K H ^a   Hung, W C ^a,c   Shiea, J ^a,c   Su, Y C ^a   Kao, C H ^a   Chen, B M ^d   Roffler, S ^d   Cheng, T L ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

glucuronidase; Glucuronide prodrug; Luminescence; Non invasive imaging; Optical imaging; Prodrug activating bacteria

Indexed keywords

9 AMINOCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN GLUCURONIDE; BETA GLUCURONIDASE; CAMPTOTHECIN DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVATION; DRUG HYDROLYSIS; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE CLUSTER; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TARGET ORGAN; TUMOR XENOGRAFT;

ANIMALS; BACTERIA; GLUCURONIDASE; GLUCURONIDES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PRODRUGS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS;

EID: 43749092582     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.10     Document Type: Article

References (42)

1. Higuchi T. Pharmacy, pharmaceutics and modern drug delivery. Am J Hosp Pharm 1976; 33: 795-800.
2. Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Clin Pharmacokinet 1985; 10: 377-391.
3. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 1994; 54: 2719-2723.
4. Cheng TL, Wei SL, Chen BM, Chern JW, Wu MF, Liu PW et al. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer 1999; 79: 1378-1385.
5. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88: 8039-8043.
6. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 2004; 101: 15172-15177.
7. Cheong I, Huang X, Bettegowda C, Diaz Jr LA, Kinzler KW, Zhou S et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006; 314: 1308-1311.
8. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57: 4537-4544.
9. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005; 102: 755-760.
10. FujimoriM, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 2002; 5: 200-203.
11. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004; 22: 313-320.
12. Seo N, Tokura Y. Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res 1999; 19: 555-561.
13. Seo N, Hayakawa S, Tokura Y. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 2002; 12: 291-300.
14. Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med 1999; 189: 231-239.
15. Ivanov VN, Krasilnikov M, Ronai Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2002; 277: 4932-4944.
16. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-2329.
17. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22: 657-682.
18. Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW, Roffler SR. Poly(ethylene glycol) modification of betaglucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother 1997; 44: 305-315.
19. Chen BM, Chan LY, Wang SM, Wu MF, Chern JW, Roffler SR. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Int J Cancer 1997; 73: 392-402.
20. Chen BM, Cheng TL, Tzou SC, Roffler SR. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int J Cancer 2001; 94: 850-858.
21. Liang WJ, Wilson KJ, Xie H, Knol J, Suzuki S, Rutherford NG et al. The gusBC genes of Escherichia coli encode a glucuronide transport system. J Bacteriol 2005; 187: 2377-2385.
22. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17: 353-360.
23. Lin TP, Chen CL, Chang LK, Tschen JS, Liu ST. Functional and transcriptional analyses of a fengycin synthetase gene, fenC, from Bacillus subtilis. J Bacteriol 1999; 181: 5060-5067.
24. Xi L, Cho KW, Tu SC. Cloning and nucleotide sequences of lux genes and characterization of luciferase of Xenorhabdus luminescens from a human wound. J Bacteriol 1991; 173: 1399-1405.
25. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E. Antineoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1991; 42: 2062-2065.
26. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695-712.
27. 2 tension measurements. Cancer Res 1991; 51: 3316-3322.
28. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
29. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-8941.
30. Bakina E, Wu Z, Rosenblum M, Farquhar D. Intensely cytotoxic anthracycline prodrugs: glucuronides. J Med Chem 1997; 40: 4013-4018.
31. Schmidt F, Monneret C. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg Med Chem 2003; 11: 2277-2283.
32. de Bont DB, Leenders RG, Haisma HJ, van der Meulen-Muileman I, Scheeren HW. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorg Med Chem 1997; 5: 405-414.
33. Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995; 38: 5051-5065.
34. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM et al. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther 2007; 14: 187-200.
35. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003; 2003: 48-70.
36. Fishman WH. The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Tumour Biol 1995; 16: 394-402.
37. Fishman WH, Kato K, Anstiss CL, Green S. Human serum beta-glucuronidase; its measurement and some of its properties. Clin Chim Acta 1967; 15: 435-447.
38. Aldridge BE, Bruner LJ. Pressure effects on mechanisms of charge transport across bilayer membranes. Biochim Biophys Acta 1985; 817: 343-354.
39. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006; 208: 290-298.
40. Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer 2007; 43: 490-496.
41. Bermudes D, Low B, Pawelek J. Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol 2000; 465: 57-63.
42. Bereta M, Hayhurst A, Gajda M, Chorobik P, Targosz M, Marcinkiewicz J et al. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine 2007; 25: 4183-4192.